[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618548":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":59,"collaborators":63,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":26,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":26,"enrollmentInfo":99,"targetDuration":26,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TAIC Group","EXPERIMENTAL","Patients in the TAIC group will undergo FOLFOX-based TAIC combined with either cetuximab or bevacizumab on weeks 0 and 4, and will receive FOLFOX-based IVC combined with either cetuximab or bevacizumab on weeks 2 and 6. During each TAIC, based on the tumor's vaIVCular supply, the Seldinger technique is used to puncture the right femoral artery, and a microcatheter is inserted into the arterial branch of the superior mesenteric artery, inferior mesenteric artery, or common iliac artery, which is predominantly feeding the tumor. Chemotherapy drugs will be administered via the microcatheter. The FOLFOX-based TAIC consists of oxaliplatin (85 mg\u002Fm²) administered as a 2 hours transarterial infusion, leucovorin (400 mg\u002Fm²) administered as a 2 hours transarterial infusion, and fluorouracil (2400 mg\u002Fm²) administered as a 44 hours transarterial infusion, followed by intravenous administration of bevacizumab (5 mg\u002Fkg) or cetuximab (500 mg\u002Fm²). The IVC regimen is the same as that in the IVC group",[13],"Procedure: Transarterial infusion chemotherapy (TAIC)",{"label":15,"type":16,"description":17,"interventionNames":18},"IVC group","ACTIVE_COMPARATOR","Patients in the IVC group will receive FOLFOX-based IVC combined with either cetuximab or bevacizumab every two weeks for a total of 8 weeks. The FOLFOX regimen consists of oxaliplatin (85 mg\u002Fm²) administered as a 2 hours intravenous infusion, leucovorin (400 mg\u002Fm²) administered as a 2 hours intravenous infusion, and fluorouracil (2400 mg\u002Fm²) administered as a 44 hours intravenous infusion, followed by intravenous administration of bevacizumab (5 mg\u002Fkg) or cetuximab (500 mg\u002Fm²).\n\nCetuximab is used for the treatment of RAS\u002FBRAF wild-type left-sided CRC, while bevacizumab is used for the treatment of RAS\u002FBRAF wild-type right-sided CRC and RAS\u002FBRAF mutant CRC regardless of tumor location.",[19],"Procedure: Intravenous Chemotherapy（IVC）",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Transarterial infusion chemotherapy (TAIC)","TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Intravenous Chemotherapy（IVC）","Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.",[15],[32],{"name":33,"affiliation":5,"role":34},"Quanda Liu, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Quanda Liu Chief physician, MD","CONTACT","01088001037","hnzyydxwjp@163.com",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":40},"Junpeng Wang, MD",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":26,"geoPoint":26,"contacts":52},"Guang'anmen Hospital, China Academy of Chinese Medical Sciences","RECRUITING","Xicheng","Beijing Municipality","100053","China","CN",[53,54,55,57],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":26,"role":38,"phone":26,"phoneExt":26,"email":40},{"name":56,"role":34,"phone":26,"phoneExt":26,"email":26},"Liuxin Duan, MD",{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},"Li Yao, MD",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Quanda Liu","Chief physician",[64,66,69,71,73,76,78,80,82,84,86,88],{"name":65,"class":6},"Liaoning Cancer Hospital & Institute",{"name":67,"class":68},"The Rocket Force Characteristic Medical Center","UNKNOWN",{"name":70,"class":6},"Second Affiliated Hospital of Nanchang University",{"name":72,"class":6},"Affiliated Hospital of Hebei University",{"name":74,"class":75},"The First Hospital of Qinhuangdao","OTHER_GOV",{"name":77,"class":68},"The Central Hospital of Handan City",{"name":79,"class":68},"The First People's Hospital of Jiujiang City",{"name":81,"class":6},"Changzhi Medical College",{"name":83,"class":68},"Zibo Boshan District Traditional Chinese Medicine Hospital",{"name":85,"class":68},"Linshu County People's Hospital",{"name":87,"class":68},"Hebei Yixian Hospital",{"name":89,"class":68},"Baoding Mancheng District People's Hospital","100618548","clinical-efficacy-of-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-100618548",false,"NCT07333053","Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Colorectal cancer confirmed by CT\u002FMRI and colonoscopic biopsy；\n3. Patients unfit for surgery due to poor general condition or tumor extent and location;\n4. Patients who have not received prior chemotherapy or those who have undergone prior chemotherapy but remain chemosensitive.\n5. Adequate haematological, heart, liver and renal functions are required, with the following specific criteria: white blood cell count≥4000\u002FmL, neutrophils≥1500\u002Fmm³, platelets≥100×10⁹\u002FL, haemoglobin≥10.0 g\u002FL, total bilirubin 2.0 mg\u002FdL, aspartate aminotransferase 100 IU\u002FL, alanine aminotransferase 100 IU\u002FL, serum creatinine 1.5 mg\u002FdL or creatinine clearance rate≥60 mL\u002Fmin\u002Fbody, and urine protein\u002Fcreatinine\\\u003C1.\n6. Patients have to have an expected life expectancy of ≥3months.\n7. All the subjects in this study are required to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with other primary malignant tumors;\n2. Patients with gastrointestinal perforation;\n3. Patients are allergic to the antitumor agents;\n4. Women who are pregnant, breastfeeding, or planning to become pregnant;\n5. Patients who receive other antitumor therapies concurrently, such as chemotherapy, targeted therapy, or radiotherapy;\n6. Patients with MSI-H\u002FdMMR CRC；\n7. Patients for whom participation in the study is deemed to be inappropriate by the doctor in charge and\u002For the investigator for any other reasons.","ALL","18 Years",{"count":100,"type":101},30,"ESTIMATED","INTERVENTIONAL",[104],"NA","This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).",[107],"Unresectable Colorectal Cancer",[109,110,111,112,113,114,115],"Transarterial Infusion Chemotherapy","Bevacizumab","Cetuximab","Colorectal Cancer","FOLFOX Protocol","Unresectable","Clinical Trial","2026-03-05",{"date":118,"type":119},"2026-03-06","ACTUAL",{"date":121,"type":101},"2026-03-31",{"date":123,"type":101},"2027-12-31",{"name":61,"class":6},1]